Close Menu

financial guidance

The Danish firm's research business grew 24 percent and its North American revenues grew 52 percent.

The firm's revenues were hit by currency translation and differences in the timing of test reimbursement compared with the previous year's quarter.

The company provided preliminary 2015 revenue guidance of $175 million to $190 million.

The company's chairman and CEO said that PositiveID has a sizeable backlog and pipeline of revenue opportunities for 2015. 

During its second quarter earnings call, Myriad officials detailed the market prospects for its tumor and germline BRACAnalysic CDx tests.

The preliminary revenues are on par with the average analyst estimate of $33.3.

The company initiated guidance for 2015 at a range of $4.35 to $4.45 per share.

 

NEW YORK (GenomeWeb) – Meridian Bioscience today released its revenue and earnings per share guidance for fiscal year 2015, coming in below Wall Street expectations.

NEW YORK (GenomeWeb) – Before the US Food and Drug Administration's draft guidance on laboratory-developed tests (LDTs) can be finalized, the agency will need to iron out with industry players several areas of regulation that remain unclear and confront old issues around the agency's authority ov

NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market Tuesday a 17 percent year-over-year increase in its revenues driven by its hereditary cancer tests.

Pages

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.